DDA platform, as a leading division of Creative Bioarray, whose mission focuses on developing unique technologies and providing high quality biotechnology products and services for worldwide researchers, is excited to announce the in vitro ADME service that can be widely applied to accelerate the process of drug discovery through allowing researchers to characterize drug candidate's ADME properties and its potential for drug interactions. —
In vitro ADME analysis is an important component of a successful drug development program that contributes to critical decision-making processes by providing metabolic information about absorption, pharmacokinetics, drug interactions and potential toxicity. DDA platform provides comprehensive in vitro ADME services for drug discovery organizations. Many of our in vitro ADME analytical methods come in diverse forms to accommodate different stages of the drug development process, allowing us to provide a flexible approach to ADME services, such as we can perform extensive automated in vitro assays under GLP conditions to obtain information on metabolism, toxicity and physicochemical properties.
It will be best to determine the ADME characteristics of the chemical series or drug candidate and its potential drug interaction properties as early as possible. Through more targeted chemical synthesis and advances in the correct compounds, this can definitely help reduce the risk of candidate molecules and increase project productivity.
In addition to providing standard procedures for each test method, the experienced research team in DDA platform can also help design custom best strategies and solutions to meet any drug discovery needs. For example, permeability, as an important factor affecting oral absorption, blood-brain barrier penetration, and drug delivery to tissues and across cell membranes, being determined by passive permeability and the sensitivity of the drug to the efflux or uptake of the drug transporter. DDA platform offers a wide range of complementary in vitro models to assess drug permeability and predict drug absorption and distribution.
Besides, plasma stability assay is also one of our in vitro ADME screening services. DDA platform delivers cost-effective, consistent, high-quality data in a highly automated way, helping researchers determine the stability of compounds in plasma, thereby driving pharmacokinetics and clinical development. As for the CYP induction analysis, it is designed to cost-effectively evaluate more compounds simultaneously. The potential drug interactions of compounds can be understood by using our CYP induction assay.
“The in vitro ADME assays in our platform are not just what we mentioned above, also include red blood cell partitioning, in vitro metabolic stability and non-CYP mediated metabolism etc. And the purpose for these assays is to promote an in-depth understanding of metabolism and potential drug interactions in the development of ADME.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Our highly trained and experienced scientific team provides clients with extensive and in-depth expertise on appropriate research design, research execution and data interpretation. Even if you have got some specific requirements, we are also capable to offer customized solutions with effective advice.”
About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, we are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.
Release ID: 88929785